Recent Price Movement and Market Context
On 5 Mar 2026, Dishman Carbogen Amcis Ltd’s stock price touched Rs.161.85, its lowest level in the past year. This new low comes after four consecutive days of declines, during which the stock has lost approximately 12.05% in value. Despite an intraday high of Rs.167.70, representing a 2.16% gain on the day, the stock closed with a day change of -0.88%, underperforming its Pharmaceuticals & Biotechnology sector by 1.9%.
The stock is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained downward momentum. This contrasts with the broader market, where the Sensex opened 414.29 points higher and is currently trading at 79,583.92, up 0.59%. Notably, the NIFTY CPSE index hit a new 52-week high on the same day, highlighting the divergence between Dishman Carbogen Amcis Ltd and broader market trends.
Long-Term Performance and Valuation Metrics
Over the past year, Dishman Carbogen Amcis Ltd has delivered a negative return of 22.34%, significantly lagging behind the Sensex’s positive 7.96% return. The stock’s 52-week high was Rs.321.15, indicating a substantial decline of nearly 50% from its peak. This underperformance extends beyond the last year, with the stock also trailing the BSE500 index over the last three years and the past three months.
From a valuation perspective, the company’s Return on Capital Employed (ROCE) remains weak at an average of 0.97%, reflecting limited efficiency in generating returns from its capital base. The company’s net sales have grown at a modest annual rate of 8.10% over the last five years, which is below expectations for a growth-oriented pharmaceutical entity. Furthermore, the company’s debt servicing capacity is constrained, with a high Debt to EBITDA ratio of 4.96 times, indicating elevated leverage relative to earnings before interest, taxes, depreciation, and amortisation.
Crushing the market! This Small Cap from Aerospace & Defense just earned its spot in our Top 1% with impressive gains. Don't let this opportunity slip through your hands.
- - Recent Top 1% qualifier
- - Impressive market performance
- - Sector leader
Quarterly Financial Performance
The company’s quarterly financials reveal further pressures. The Profit After Tax (PAT) stood at a negative Rs.12.97 crores, representing a steep decline of 403.0% compared to the previous quarter. Operating profit to interest coverage is at a low 2.47 times, signalling limited buffer to meet interest obligations. Additionally, the PBDIT (Profit Before Depreciation, Interest and Taxes) for the quarter was Rs.113.11 crores, the lowest recorded in recent periods.
These figures underscore the challenges faced by Dishman Carbogen Amcis Ltd in maintaining profitability and managing financial costs, which have contributed to the stock’s downward trajectory.
Institutional Investor Activity
Institutional investors have reduced their holdings by 0.51% over the previous quarter, now collectively holding 8.93% of the company’s shares. This decline in institutional participation may reflect cautious sentiment among investors with greater analytical resources and insight into the company’s fundamentals.
The reduced institutional stake aligns with the stock’s underperformance and the company’s current financial metrics, signalling a cautious stance from market participants with significant capital.
Valuation and Comparative Analysis
Despite the challenges, Dishman Carbogen Amcis Ltd’s valuation metrics present some contrasting signals. The company’s ROCE of 3.2, while modest, is accompanied by a very attractive Enterprise Value to Capital Employed ratio of 0.5. This suggests the stock is trading at a discount relative to its capital base and peers’ historical valuations.
Moreover, the company’s profits have risen by 233.1% over the past year, despite the stock’s negative return of 22.34%. This disparity is reflected in a low PEG ratio of 0.1, indicating that the stock’s price has not kept pace with earnings growth. However, these valuation factors have not yet translated into positive price momentum.
Considering Dishman Carbogen Amcis Ltd? Wait! SwitchER has found potentially better options in Pharmaceuticals & Biotechnology and beyond. Compare this small-cap with top-rated alternatives now!
- - Better options discovered
- - Pharmaceuticals & Biotechnology + beyond scope
- - Top-rated alternatives ready
Mojo Score and Ratings
Dishman Carbogen Amcis Ltd currently holds a Mojo Score of 17.0, with a Mojo Grade of Strong Sell as of 12 Jan 2026, upgraded from a previous Sell rating. The Market Cap Grade stands at 3, reflecting the company’s relatively modest market capitalisation within its sector. These ratings encapsulate the company’s financial and market performance, signalling caution in the current environment.
Sector and Market Comparison
Within the Pharmaceuticals & Biotechnology sector, Dishman Carbogen Amcis Ltd’s recent performance contrasts with broader market trends. While the Sensex and sector indices have shown resilience and gains, this stock’s persistent decline and valuation metrics highlight its divergence from sector peers. The stock’s underperformance relative to the BSE500 index over multiple time frames further emphasises this point.
Summary of Key Metrics
To summarise, the stock’s key metrics as of 5 Mar 2026 include:
- New 52-week low price: Rs.161.85
- One-year return: -22.34%
- Debt to EBITDA ratio: 4.96 times
- Average ROCE: 0.97%
- Quarterly PAT: -Rs.12.97 crores (-403.0%)
- Operating profit to interest coverage: 2.47 times
- PBDIT (quarterly): Rs.113.11 crores
- Institutional holding: 8.93% (down 0.51% last quarter)
- Mojo Score: 17.0 (Strong Sell)
These figures collectively illustrate the factors contributing to the stock’s recent decline and its current valuation status within the Pharmaceuticals & Biotechnology sector.
Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →
